Signal
3 articles covering "personalized-medicine"
Six-year follow-up from a 16-patient Phase 1 trial of autogene cevumeran shows unprecedented survival rates in one of oncology's deadliest cancers, now entering a global Phase 2 trial.
A first-in-human trial published in Nature shows BioNTech's individualized neoantigen mRNA vaccine produces durable T cell immunity and sustained disease control in aggressive breast cancer.
The FDA's new Plausible Mechanism Pathway enables approval of one-patient gene editing therapies without traditional clinical trials, inspired by the first personalized CRISPR cure for an infant with a fatal metabolic disorder — but ethicists warn of a regulatory Pandora's box.